Decibel Therapeutics, Inc.

Regeneron Pharmaceuticals, Inc. ’s employee count grew from around 8,000 positions in 2019 to almost 13,500 in 2023. Alongside this expansion in personnel, the company has doubled its R&D spend – inve

Regeneron Pharmaceuticals, Inc. 's acquisition of Decibel Therapeutics, Inc. last year is looking like a very smart move after the gene therapy at the heart of the deal restored hearing to normal le

Regeneron Pharmaceuticals, Inc. has many moving parts to prioritize this year as it transitions patients to a new version of its blockbuster ophthalmology drug Eylea (aflibercept), expands the use of

There are no approved pharmacological therapies for congenital hearing loss and this situation is unlikely to change any time soon. Still, a glimmer of hope has been provided with signs of hearing imp